Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024.

About Climb Bio, Inc. Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.

InvestorsChris Brinzey ICR Westwickechris.brinzey@westwicke.com 339-970-2843

MediaJon YuICR Westwickejon.yu@westwicke.com475-395-5375

Climb Bio (NASDAQ:CLYM)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025 Click aqui para mais gráficos Climb Bio.
Climb Bio (NASDAQ:CLYM)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025 Click aqui para mais gráficos Climb Bio.